Clinical Advisory Board
The marketplace success of novel therapeutics, diagnostics, medical devices, and other healthcare products often depends on nuanced factors that require frontline clinician feedback to assess. The Clinical Advisory Board (CAB) is a group of physician volunteers who leverage their networks to connect UCeed Health staff to frontline clinicians who provide feedback on the clinical utility and feasibility of healthcare products and services in development by prospective investee companies. We are deeply grateful for their valuable assistance.
Child Health Fund Portfolios
AazeinTx is commercializing a novel, fast-acting, orally delivered compound for the treatment of acute and chronic asthma.
Child Health Imprints
Child Health Imprints is giving preterm babies a better chance at life with data-monitoring technology that supports clinicians.
Fluid Biomed is revolutionizing the approach to vascular disease by creating the first bioabsorbable brain stent to treat aneurysms.
Nimble Science is developing an ingestible medical device capsule that samples small intestine contents for microbiome diagnostic applications obviating the need for invasive endoscopy procedures.
Noa Therapeutics is developing multimodal therapeutics to address the complexity of immune diseases, innovation that will help break the cycle of trial-and-error treatment failures.
Trexo Robotics has developed a sophisticated wearable robotic device to provide physiotherapy for children with walking impairments. The device monitors a child’s ability to move their legs with artificial intelligence algorithms and provides a level of assistance that maximizes therapeutic benefit.
True Angle — a medical technology company focusing on disorders that affect an aging market — has developed unique at-home solutions, allowing people to get better and more convenient care.
Xploro Inc. uses artificial intelligence to ease procedural anxiety and reduce stress in children with cancer.
Zymedyne is developing therapeutics for the treatment of chronic pain that targets a recently discovered biological process that is abnormally activated in chronic pain conditions, offering an alternative to opioids.